Results 21 to 30 of about 1,071 (121)

Comparison between [⁶⁸Ga]Ga-FAPI-46 and [¹⁸F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer. [PDF]

EJNMMI Res
Abstract Background Fibroblast activation protein (FAP)–targeted tracers have emerged as promising agents for breast cancer imaging, with recent studies demonstrating PET performance comparable to or surpassing, that of [ 18 F ...
Küper AT, Vaz SC, Pabst KM, Ciuciulkaite I, Mavroeidi IA, Hamacher R, Welt A, Hammersen N, Costa PF, Djaileb L, Seifert R, Umutlu L, Schuler M, Herrmann K, Fendler WP, Kümmel S, Kersting D.   +16 more
europepmc   +3 more sources

Automated synthesis of [⁶⁸Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types. [PDF]

EJNMMI Radiopharm Chem, 2022
Abstract Background The recent development of quinoline-based radiotracers, which act as fibroblast activation protein inhibitors (FAPIs), has shown promising preclinical and clinical advantages. [68Ga]Ga-FAPI-46 is a new radiotracer for in vivo detection of the fibroblast activation protein by positron emission ...
Alfteimi A, Lützen U, Helm A, Jüptner M, Marx M, Zhao Y, Zuhayra M.   +6 more
europepmc   +5 more sources

Potential value of [⁶⁸Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis. [PDF]

Eur J Nucl Med Mol Imaging
Abstract Purpose [ 68 Ga]Ga-FAPI-46 has shown promise for urothelial cancer (UC) detection. This study evaluates its diagnostic value versus contrast-enhanced CT (ceCT) and 2-[ 18 F ...
Pabst KM, Siegmund SC, Holzgreve A, Schmid HP, Bartel T, Herrmann K, Küper AT, Aydogdu C, Kersting D, Kesch C, Hadaschik BA, Unterrainer M, Stief CG, Cyran CC, Werner RA, Fendler WP, Casuscelli J, Unterrainer LM.   +17 more
europepmc   +4 more sources

Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial. [PDF]

BMC Cancer
Abstract Background [18F]Fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) is recommended during diagnostic work-up for ovarian cancer; however, [18F]FDG PET has several inherent limitations. The novel oncologic PET-tracer fibroblast activation protein inhibitor (FAPI) has demonstrated promising results in
Bentestuen M, Ladekarl M, Knudsen A, Zacho HD.   +3 more
europepmc   +5 more sources

Swin UNETR-based prediction of [⁶⁸Ga]Ga-FAPI-46 PET/CT dose rate maps in cancer patients: quantitative comparison with [¹⁸F]FDG PET/CT. [PDF]

BMC Med Imaging
Izadi-Yazdi S, Babapour-Mofrad F, Yazdani E, Karamzade-Ziarati N, Arabi H, Sadeghi M.   +5 more
europepmc   +2 more sources

Comparison of diagnostic performance of [⁶⁸Ga]-Ga-FAPI-46 and [¹⁸F]-FDG PET/CT imaging for the detection of lesions and disease staging in patients with breast cancer. [PDF]

Asia Ocean J Nucl Med Biol
To compare the diagnostic performance of [68Ga]-Ga-FAPI-46 and [18F]-FDG PET/CT imaging for the detection of lesions and disease staging in breast cancer.Twelve female patients with breast cancer (mean age= 49.2±13.29 years) and previous [18F]-FDG PET/CT were recruited in the study.
Radmehr K, Farzanefar S, Abbasi M, Salehi Y, Karamzade-Ziarati N, Emami-Ardekani A, Manafi-Farid R, Vahidfar N, Beiki D.   +8 more
europepmc   +4 more sources

Production and Quality Control of [⁶⁸Ga]Ga-FAPI-46: Development of an Investigational Medicinal Product Dossier for a Bicentric Clinical Trial. [PDF]

Pharmaceuticals (Basel)
Background/Objectives: Fibroblast activation protein (FAP) is highly expressed in tumor stroma and selected inflammatory conditions, offering a promising target for molecular imaging. [68Ga]Ga-FAPI-46 is a DOTA-based FAP inhibitor with excellent tumor-to-background ratio and potential advantages over [18F]FDG in low-glycolytic tumors. This article aims
Cafaro A, Cuni C, Boschi S, Landi E, Foschi G, Monti M, Caroli P, Matteucci F, Masini C, Di Iorio V.   +9 more
europepmc   +3 more sources

AUTOMATED SYNTHESIS AND IN VITRO STUDIES OF [68GA]GA-FAPI-46 IN HOSPITAL RADIOPHARMACY

Hematology, Transfusion and Cell Therapy
Introduction/Justification: Early evidence appointed fibroblast activation protein (FAP), a type II transmembrane serine protease, as highly expressed in the stroma of various tumor entities, designating FAP as the next target for cancer studies in nuclear medicine.
Leonardo Lima Fuscaldi, Paloma Caiado Lupinari, Karen Alessandra Kazumi Sato, Ana Claudia Camargo Miranda, Solange Nogueira Amorim, Taise Vitor, Jairo Wagner, Vasko Kramer, Lilian Yuri Itaya Yamaga, Luciana Malavolta, Marycel Figols de Barboza   +10 more
openaire   +2 more sources

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe

Advanced Science, Volume 13, Issue 38, 9 July 2026.
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao, Wenzhu Hu, Du Tang, Xinxin Liu, Kun Yu, Lixia Feng, Minyu Liao, Wang Lin, Wenqiang Zhu, Sanjay Rajagopalan, Xiaoli Lan, Jixin Zhong, Dao Wen Wang, Dawei Jiang, Xiaoquan Rao   +14 more
wiley   +1 more source

A FAP‐Targeted SMDC Platform Enables Synergistic Radionuclide–Chemotherapy with PET‐Guided Evaluation

Advanced Science, Volume 13, Issue 36, 29 June 2026.
A fibroblast activation protein (FAP)‐targeted small molecule–drug conjugate (SMDC) platform is developed to integrate PET imaging with synergistic radionuclide–chemotherapy. Linker chemistry governs stability, exposure, and tolerability, with the VC linker providing superior in vivo performance.
Ruitao Yang, Hongxin Li, Zexin Xu, Baocheng Chen, Ningjie Li, Yuhua Zhong, Kongzhen Hu   +6 more
wiley   +1 more source